Neurocrine Biosciences (NBIX) Outstanding Biotech Player; Mistras Group (MG) Surpasses Estimates


Neurocrine Biosciences Inc. (Nasdaq:NBIX) shares soared more than 20% to reach the $47.25 mark in early trade Thursday after the company said that its experimental drug NBI-98854 significantly reduced tardive dyskinesia – characterized by sudden, uncontrollable movements of voluntary muscle groups – during the Kinect 3 clinical trial

NBIX stock is currently trading at $43.69, up $4.76 (or +12.23%), and 2,041,783 of its shares exchanged hands so far, a large increase in activity versus its average volume (3m) of 932,248

Neurocrine Biosciences, a biopharmaceutical company, has 85.87M Shares Outstanding and NBIX 52-week range is between $15.21 and $56.97 per share



Shares of Mistras Group, Inc. (NYSE:MG) climbed over 20% in their first few minutes of trading on Thursday as the company delivered its quarterly financial results with numbers well-above analysts’ expectations

For its first quarter fiscal 2016, Mistras Group posted revenues of $179.9 million, an 8.0% increase year over year, and net income of $6.9 million, or $0.23 per diluted share, compared to net income of $1.7 million or $0.06 per diluted share in the same quarter the prior year, easily surpassing the Capital IQ Consensus Estimate of $0.09 earnings per share on revenues of $166.02 million.

109,508 shares of the company were traded so far, currently changing hands for $17.04, up $2.81 (or +19.75%)

Mistras Group, a leading “one source” global provider of technology-enabled asset protection solutions, has 28.86M Shares Outstanding and MG stock 52-week range is $12.65 – $21.60 per share


Disclaimer: The disclaimer is to be read and fully understood before using our site, or joining our email list. GalaxyStocks is not a registered investment adviser. This material is for informational purposes only and should not be construed as an offer or solicitation of an offer to buy or sell securities. Investors should always conduct their own due diligence with any potential investment, with independent research and other professional advice. Read full disclaimer at